Tocqueville Asset Management L.P. Cuts Stock Position in AbbVie Inc. $ABBV

Tocqueville Asset Management L.P. cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 335,231 shares of the company’s stock after selling 11,077 shares during the quarter. AbbVie accounts for approximately 1.1% of Tocqueville Asset Management L.P.’s holdings, making the stock its 14th biggest position. Tocqueville Asset Management L.P.’s holdings in AbbVie were worth $77,619,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ellenbecker Investment Group raised its position in AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after buying an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA boosted its holdings in shares of AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after acquiring an additional 45 shares in the last quarter. Matthew Goff Investment Advisor LLC increased its stake in shares of AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after acquiring an additional 45 shares during the period. Centennial Wealth Advisory LLC increased its stake in shares of AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after acquiring an additional 45 shares during the period. Finally, Willner & Heller LLC raised its holdings in AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after purchasing an additional 46 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the topic of a number of analyst reports. Evercore lowered their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. William Blair reissued an “outperform” rating on shares of AbbVie in a research note on Monday. Barclays initiated coverage on AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Royal Bank Of Canada began coverage on AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target on the stock. Finally, UBS Group cut their price objective on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Trading Down 1.2%

Shares of NYSE ABBV traded down $2.69 during trading on Friday, reaching $222.68. The company had a trading volume of 750,568 shares, compared to its average volume of 7,076,792. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a 50-day moving average price of $224.52 and a two-hundred day moving average price of $224.48. The stock has a market capitalization of $393.73 billion, a PE ratio of 94.21, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insider Transactions at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.25% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple analyst takes and upgrades support upside expectations — AbbVie has a consensus “Moderate Buy” and RBC Capital started coverage with an Outperform rating and $260 price target, signaling analyst confidence in growth prospects. AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Analysts
• Positive Sentiment: Early-stage clinical progress: AbbVie reported encouraging Phase 1 results for ABBV-295 and is advancing a risankizumab dosing study — both reinforce ongoing R&D momentum in immunology and targeted therapeutics. These readouts support longer-term growth optionality. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: Allergan Aesthetics (part of AbbVie’s portfolio) continues brand strength: a top New York provider was again named #1 by Allergan Aesthetics, a small near-term signal that the aesthetics business remains competitive. New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
• Neutral Sentiment: Mixed analyst valuation view: some models lift upside tied to immunology growth while others highlight competition risk; fair-value estimates have moved only slightly, implying limited near-term re-rating. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks
• Neutral Sentiment: Broader market and sector narratives (biotech growth resilience, psychiatric market expansion) provide context but are unlikely to move the stock materially absent company-specific catalysts. Josh Brown: Biotech growth stocks immune to disruption risk
• Negative Sentiment: Competitive pressure: UCB’s Bimzelx outperformed AbbVie’s Skyrizi in psoriatic arthritis, which raises near-term sales risk and may damp investor confidence in market share for a key immunology product. AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
• Negative Sentiment: Executive pay spike: reports that AbbVie’s CEO compensation rose above $30M may attract shareholder scrutiny on governance and costs. J&J, AbbVie CEOs See Pay Spike to More Than $30M

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.